DYN Q3 2021 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$43M

Net Income

-$43M

EPS (Diluted)

$-0.83

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$467M

Total Liabilities

$53M

Stockholders' Equity

$414M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$43M	-$14M	-216.3%
Net Income	-$43M	-$14M	-205.9%